These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Emergence of taxis and synergy in angiogenesis. Capogrosso Sansone B; Scalerandi M; Condat CA Phys Rev Lett; 2001 Sep; 87(12):128102. PubMed ID: 11580561 [TBL] [Abstract][Full Text] [Related]
43. Molecular mechanisms of tumor angiogenesis and tumor progression. Cavallaro U; Christofori G J Neurooncol; 2000; 50(1-2):63-70. PubMed ID: 11245282 [TBL] [Abstract][Full Text] [Related]
44. Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies. Dutour A; Rigaud M Anticancer Res; 2005; 25(6B):3799-807. PubMed ID: 16309166 [TBL] [Abstract][Full Text] [Related]
45. Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development. Galbraith SM Br J Radiol; 2003; 76 Spec No 1():S83-6. PubMed ID: 15456717 [No Abstract] [Full Text] [Related]
46. Heparin derivatives as angiogenesis inhibitors. Presta M; Leali D; Stabile H; Ronca R; Camozzi M; Coco L; Moroni E; Liekens S; Rusnati M Curr Pharm Des; 2003; 9(7):553-66. PubMed ID: 12570803 [TBL] [Abstract][Full Text] [Related]
47. Rationale, problems and perspectives in anti-angiogenic therapy. Lorusso G; Dell'Eva R; Vené R; Pfeffer U; Albini A Tumori; 2001; 87(6):S17-9. PubMed ID: 11989611 [No Abstract] [Full Text] [Related]
48. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Raza A; Franklin MJ; Dudek AZ Am J Hematol; 2010 Aug; 85(8):593-8. PubMed ID: 20540157 [TBL] [Abstract][Full Text] [Related]
49. Role of the tumor stroma in resistance to anti-angiogenic therapy. Huijbers EJ; van Beijnum JR; Thijssen VL; Sabrkhany S; Nowak-Sliwinska P; Griffioen AW Drug Resist Updat; 2016 Mar; 25():26-37. PubMed ID: 27155374 [TBL] [Abstract][Full Text] [Related]